Breaking: Four months ago, we set up Claude up with a brand new $50,000 portfolio to see how well it does at picking stocks So far, it's worked. Claude is up 14% while the $SPY is up 10% in that same time period Here's it's current picks + the reasoning behind them "The AI build-out, my biggest theme: $NOW - 13%. The software big companies run their operations on, now becoming the place they plug in AI agents. That shift is real and the price has not fully caught up to it. My largest position. (Up 25%) $ZETA, 10%. An AI advertising company that has beaten and raised its forecast 19 quarters straight, with a deal whose economics are not yet in the numbers Wall Street uses. (Up 32%) $VST - 9%. It sells power to AI data centers, and the market is valuing today's business while ignoring a large earnings jump and a big acquisition that are both still coming. (Down 5%) $AVGO - 3%. Its AI chip orders are booked years out, which gives me more certainty about the growth than the market is crediting. (Up 21%) $MGNI - 4%. I already banked part of a strong gain and kept a smaller piece for two free shots at upside: a coming antitrust ruling that could help it, and a cheap setup into its next report. (Up 41%) Financials I think the market has mispriced: $PGY - 7%. A fast-growing lender trading at roughly four times earnings, with the widest gap to Wall Street's price target of anything I own. (Up 20%) $PLMR - 6%. Growing more than 30 percent a year, and a calm hurricane forecast just removed the fear that was pinning it down. It also barely moves with the rest of the market. (Up 3%) $ICE - 5%. Sitting near a one-year low because investors fear interest rates, while its actual trading business runs at record activity. That gap is the opportunity. (Down 17%) $INTR - 5%. A cheap, fast-growing Brazilian bank, my only emerging-market holding, and a forced seller who was pushing the stock down just finished. (Down 17%) Healthcare: $HALO - 6%. A cash machine that collects drug royalties, trades cheap, and is buying back its own stock, with a lawsuit that could add a free layer of upside. (Up 17%) $ARDX - 5%. Its main drug is growing close to 60 percent a year while the stock trades below what I think the business is worth. The highest expected return in my book. (Down 16%) Two more, away from the crowd: $KTOS - 5%. A growing pile of defense orders, and real upside if US funding for drones and missile defense comes through, which is not in the price yet. (Down 18%) $QXO - 3%. A proven dealmaker rolling up an industry, trading well below Wall Street's target as a major acquisition closes. (Down 28%) I am also holding a meaningful cash reserve in Treasury bills earning around 4 percent, because July is packed with an inflation report and a Fed meeting and I would rather stay patient than force a trade into them. The method is plain. Hold a small set of names I actually believe in, stay through the noise, and move only when the reasoning changes. Four months is a start and nothing more." See following tweet for full performance + picks